ArticleScientific reports2026
Translational assessment of butyrylcholinesterase activity as a diagnostic biomarker for depression using a chemiluminescent probe.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depressive episode is a globally prevalent psychiatric condition with a complex, multifactorial etiology involving genetic and environmental factors and despite advances in biomarker research, clinical applications remain limited due to methodological inconsistencies and population variability. Butyrylcholinesterase (BChE), an enzyme involved in cholinergic transmission, has been less studied in the context of depression compared to acetylcholinesterase. Utilizing a BChE-responsive chemiluminescent probe (BCC), BChE activity was measured in a translational approach: human serum, rat plasma, and a cell culture model. First, BChE activity was assessed in patients with depression (32 unipolar depression (UD), 21 bipolar disorder with depressive episode (BD-D)) compared to controls, then changes with respect to remission were reassessed (n = 15). Second, a chronic unpredictable mild stress (CUMS) model in rats was used to assess BChE activity in response to fluoxetine treatment. Lastly, BChE activity in response to corticosterone, norepinephrine and fluoxetine was measured in a cell culture model. Results demonstrated significantly lower BChE activity in UD and BD-D patients compared to healthy controls, with restoration following remission. In rats, BChE activity correlated with stress-induced anhedonia, and fluoxetine increased BChE levels although not reaching significance. In vitro, corticosterone exposure reduced BChE activity while fluoxetine reversed this effect and norepinephrine increased BChE activity in solely exposure and subsequent fluoxetine. These findings suggest that BChE activity may serve as a diagnostic biomarker for depression and a potential indicator of treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.